Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity

Abstract

The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.

1 . A combination of a CB1 receptor antagonist or a hydrate or a pharmaceutically acceptable salt thereof and sibutramine or a hydrate or a pharmaceutically acceptable salt thereof.  
     
     
         2 . The combination according to  claim 1 , wherein the CB1 receptor antagonist is: N-piperidino-5-(4-chlorophenyl)-1(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or a pharmaceutically acceptable salt thereof.  
     
     
         3 . The combination according to  claim 1 , wherein the components of the combination are administered simultaneously, separately or spread out over time.  
     
     
         4 . The combination according to  claim 1 , wherein each component of the combination is administered in a single dose or in multiple doses.  
     
     
         5 . A composition comprising a CB1 receptor antagonist or a hydrate or a pharmaceutically acceptable salt thereof and sibutramine or a hydrate or a pharmaceutically acceptable salt thereof, and at least one compatible and pharmacologically acceptable diluent or adjuvant.  
     
     
         6 . The composition according to  claim 5 , wherein the CB1 receptor antagonist is: N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or a pharmaceutically acceptable salt thereof.  
     
     
         7 . The composition according to  claim 5 , comprising 0.5 to 10 mg of sibutramine and 0.1 to 200 mg of the CB1 receptor antagonist.  
     
     
         8 . The composition according to  claim 5 , further in combination with a pharmaceutically compatible and physiologically active product.  
     
     
         9 . The composition according to  claim 6 , further in combination with a pharmaceutically compatible and physiologically active product.  
     
     
         10 . A process for treating obesity in a mammal, comprising administering to said mammal an effective amount of at least one CB1 receptor antagonist or a hydrate or a pharmaceutically acceptable salt thereof and sibutramine or a hydrate or a pharmaceutically acceptable salt thereof.  
     
     
         11 . The process according to  claim 10 , wherein the CB1 receptor antagonist is: N-piperidino-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or a pharmaceutically acceptable salt thereof.  
     
     
         12 . The process according to  claim 10 , wherein sibutramine is administered at a concentration ranging from 0.5 to 10 mg and the CB1 receptor antagonist is administered at a concentration ranging from 0.1 to 200 mg.  
     
     
         13 . The process according to  claim 10 , wherein the CB1 receptor antagonist and sibutramine are administered simultaneously, separately or spread out over time.  
     
     
         14 . The process according to  claim 10 , wherein the CB1 receptor antagonist is administered in a single dose or in multiple doses.  
     
     
         15 . The process according to  claim 10 , wherein sibutramine is administered in a single dose or in multiple doses.